Active Pharmaceutical Ingredients Market by Manufacturing Type and Geography - Forecast and Analysis 2022-2028
Global Active Pharmaceutical Ingredients Market: About this market
active pharmaceutical ingredients market analysis considers sales from captive API and contract API. Our study also finds the sales of active pharmaceutical ingredients in Asia, Europe, North America, and ROW. In 2019, the contract API segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing demand for low-cost drugs will play a significant role in the contract API segment to maintain its market position. Also, our global active pharmaceutical ingredients market report looks at factors such as evolving API manufacturing scenarios in developing countries, increasing the number of type II drug master (DMFs), and growing need to focus on core competencies. However, growing concerns regarding outsourced APIs and capacity utilization constraints may hamper the growth of the active pharmaceutical ingredients industry over the forecast period.
Global Active Pharmaceutical Ingredients Market: Overview
Increasing number of type II drug master files (DMFs)
The market has witnessed a steady rise in the number of DMF filings over the past two decades. This is due to the increasing investments to enhance manufacturing facilities by Asian companies to meet international quality standards. In addition, market players in India are increasingly focusing on achieving compliance with standards laid by various regulatory agencies such as the US FDA, TGA, MHRA, Brazilian Health Regulatory Agency, and SAHPRA. The increasing DMF approvals by regulatory agencies are providing significant growth opportunities for API manufacturers. Such factors will lead to the expansion of the global active pharmaceutical ingredients market at a CAGR of over 6% during the forecast period.
Paradigm shift in API manufacturing
Traditionally, most of the pharmaceutical companies have been relying on their in-house capabilities for the discovery, development, and manufacturing of APIs. However, the captive API manufacturing has seen an overhaul in the last few decades as many pharmaceutical companies are focusing on outsourcing a large share of their research and manufacturing processes to CMOs or other drug manufacturing organizations. The decision to outsource an API depends on several factors, such as industry trends, the cost of acquiring new in-house technologies, and the availability of internal capacity. Outsourcing of API enables innovators as well as generic drug manufacturers to meet aggressive development timelines while capitalizing significant efficiencies in the supply chain. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global active pharmaceutical ingredients market during the forecast period 2020-2024, click here.
With the presence of several major players, the global active pharmaceutical ingredients market is fragmented. robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredients manufacturers, that include Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Jazz Pharmaceuticals Plc, Lupin Ltd., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc.
Also, the active pharmaceutical ingredients market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
active pharmaceutical ingredients market analysis considers sales from captive API and contract API. Our study also finds the sales of active pharmaceutical ingredients in Asia, Europe, North America, and ROW. In 2019, the contract API segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing demand for low-cost drugs will play a significant role in the contract API segment to maintain its market position. Also, our global active pharmaceutical ingredients market report looks at factors such as evolving API manufacturing scenarios in developing countries, increasing the number of type II drug master (DMFs), and growing need to focus on core competencies. However, growing concerns regarding outsourced APIs and capacity utilization constraints may hamper the growth of the active pharmaceutical ingredients industry over the forecast period.
Global Active Pharmaceutical Ingredients Market: Overview
Increasing number of type II drug master files (DMFs)
The market has witnessed a steady rise in the number of DMF filings over the past two decades. This is due to the increasing investments to enhance manufacturing facilities by Asian companies to meet international quality standards. In addition, market players in India are increasingly focusing on achieving compliance with standards laid by various regulatory agencies such as the US FDA, TGA, MHRA, Brazilian Health Regulatory Agency, and SAHPRA. The increasing DMF approvals by regulatory agencies are providing significant growth opportunities for API manufacturers. Such factors will lead to the expansion of the global active pharmaceutical ingredients market at a CAGR of over 6% during the forecast period.
Paradigm shift in API manufacturing
Traditionally, most of the pharmaceutical companies have been relying on their in-house capabilities for the discovery, development, and manufacturing of APIs. However, the captive API manufacturing has seen an overhaul in the last few decades as many pharmaceutical companies are focusing on outsourcing a large share of their research and manufacturing processes to CMOs or other drug manufacturing organizations. The decision to outsource an API depends on several factors, such as industry trends, the cost of acquiring new in-house technologies, and the availability of internal capacity. Outsourcing of API enables innovators as well as generic drug manufacturers to meet aggressive development timelines while capitalizing significant efficiencies in the supply chain. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global active pharmaceutical ingredients market during the forecast period 2020-2024, click here.
Competitive Landscape
With the presence of several major players, the global active pharmaceutical ingredients market is fragmented. robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredients manufacturers, that include Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Jazz Pharmaceuticals Plc, Lupin Ltd., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc.
Also, the active pharmaceutical ingredients market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
